precision medicine trial in psoriatic arthritis—first jump in the deep end.

The article discusses a study on the immunologic heterogeneity within the overall group of patients classified as having psoriatic arthritis. The authors examined the efficacy of steering the choice of biologic on a per-patient immunologic basis in the strategic arm as compared with a standard-of-care approach. The authors have addressed recent calls for novel trial design. Slight caution is warranted as the strategic arm and standard-of-care arm were different in some key factors.